Calcium	calcium	CHEMICALS	O	OTHERS	I
carbonate	carbonate	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
:	:	O	O	O	O
the	the	O	O	O	O
updated	updated	O	O	O	O
milk-alkali	milk-alkali	O	O	O	O
syndrome	syndrome	O	O	O	O
;	;	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
3	3	O	O	O	O
cases	cases	O	O	O	O
and	and	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
describe	describe	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
carbonate-induced	carbonate-induced	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
gain	gain	O	O	O	O
insights	insights	O	O	O	O
into	into	O	O	O	O
the	the	O	O	O	O
cause	cause	O	O	O	O
and	and	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
milk-alkali	milk-alkali	O	O	O	O
syndrome	syndrome	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
laboratory	laboratory	O	O	O	O
data	data	O	O	O	O
in	in	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
corrected	corrected	O	O	O	O
serum	serum	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
>	>	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
14	14	O	O	O	O
mg/dL	mg/dl	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
review	review	O	O	O	O
the	the	O	O	O	O
pertinent	pertinent	O	O	O	O
literature	literature	O	O	O	O
on	on	O	O	O	O
milk-alkali	milk-alkali	O	O	O	O
syndrome	syndrome	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
insufficiency	insufficiency	O	DISEASE	OTHERS	I
,	,	O	O	O	O
relative	relative	O	O	O	O
metabolic	metabolic	O	O	OTHERS	I
alkalosis	alkalosis	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
low	low	O	O	O	O
parathyroid	parathyroid	CHEMICALS	O	OTHERS	I
hormone	hormone	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
PTH	pth	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
PTH-related	pth-related	O	O	O	O
peptide	peptide	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
1,25-dihydroxyvitamin	1,25-dihydroxyvitamin	CHEMICALS	O	OTHERS	I
D	d	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
malignant	malignant	O	O	O	O
lesion	lesion	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
included	included	O	O	O	O
aggressive	aggressive	O	O	O	O
hydration	hydration	O	O	O	O
and	and	O	O	O	O
varied	varied	O	O	O	O
amounts	amounts	O	O	O	O
of	of	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
higher	higher	O	O	O	O
serum	serum	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
concentrations	concentrations	O	O	O	O
received	received	O	O	O	O
pamidronate	pamidronate	O	O	OTHERS	I
intravenously	intravenously	O	O	O	O
(	(	O	O	O	O
60	60	O	O	O	O
and	and	O	O	O	O
30	30	O	O	O	O
mg	mg	O	O	OTHERS	I
,	,	O	O	O	O
respectively	respectively	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
caused	caused	O	O	O	O
severe	severe	O	O	O	O
hypocalcemia	hypocalcemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
2	2	O	O	O	O
were	were	O	O	O	O
ingesting	ingesting	O	O	O	O
acceptable	acceptable	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
elemental	elemental	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
g	g	O	O	O	O
and	and	O	O	O	O
2	2	O	O	O	O
g	g	O	O	O	O
daily	daily	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
form	form	O	O	O	O
of	of	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
carbonate	carbonate	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
to	to	O	O	O	O
our	our	O	O	O	O
highlighted	highlighted	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
review	review	O	O	O	O
the	the	O	O	O	O
history	history	O	O	O	O
,	,	O	O	O	O
classification	classification	O	O	O	O
,	,	O	O	O	O
pathophysiologic	pathophysiologic	O	O	O	O
features	features	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
milk-alkali	milk-alkali	O	O	O	O
syndrome	syndrome	O	O	O	O
and	and	O	O	O	O
summarize	summarize	O	O	O	O
the	the	O	O	O	O
cases	cases	O	O	O	O
reported	reported	O	O	O	O
from	from	O	O	O	O
early	early	O	O	O	O
1995	1995	O	O	O	O
to	to	O	O	O	O
November	november	O	O	O	O
2003	2003	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Milk-alkali	milk-alkali	O	O	O	O
syndrome	syndrome	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
common	common	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
unexplained	unexplained	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
precipitated	precipitated	O	O	O	O
by	by	O	O	O	O
small	small	O	O	O	O
amounts	amounts	O	O	O	O
of	of	O	O	O	O
orally	orally	O	O	O	O
ingested	ingested	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
carbonate	carbonate	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
susceptible	susceptible	O	O	O	O
persons	persons	O	O	O	O
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
with	with	O	O	O	O
hydration	hydration	O	O	O	O
,	,	O	O	O	O
furosemide	furosemide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
D	d	CHEMICALS	O	OTHERS	I
source	source	O	O	O	O
is	is	O	O	O	O
adequate	adequate	O	O	O	O
.	.	O	O	O	O

Pamidronate	pamidronate	O	O	OTHERS	I
treatment	treatment	O	O	O	O
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
considerable	considerable	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
hypocalcemia	hypocalcemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
even	even	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
initially	initially	O	O	O	O
severe	severe	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

